Form 4: Director Spencer Berthelsen Executes IONS Stock Sale
Statement of Changes in Beneficial Ownership
Ionis Pharmaceuticals Director Spencer R. Berthelsen exercised options and sold 8,000 shares of common stock under a 10b5-1 plan.
Summary
- Director Spencer R. Berthelsen exercised 8,000 stock options at a strike price of $24.42.
- Following the exercise, the director sold 8,000 shares of common stock at a market price of $73.49.
- The transactions were executed on June 15, 2026, pursuant to a Rule 10b5-1 trading plan adopted on September 12, 2025.
- The director maintains a direct beneficial ownership of 156,013 shares following these transactions.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as the sale was conducted under a pre-established 10b5-1 plan and represents a standard liquidity event for a director.
Positives
- The transaction was pre-planned under a Rule 10b5-1 trading plan, indicating the sale was not based on non-public information.
Negatives
- The transaction represents a divestment of equity by a member of the board of directors.
Risks
- Insider selling can sometimes be perceived by the market as a lack of confidence in future share price appreciation, though this was a pre-planned sale.
Future Outlook
No forward-looking guidance provided in this filing.
Industry Context
StockSavvy.ai notes that routine insider selling via 10b5-1 plans is common in the biotechnology sector as directors manage personal liquidity and diversify portfolios, and it generally does not signal a change in company fundamentals.
Comparison to Industry Standards
- The use of Rule 10b5-1 plans is the industry standard for corporate insiders to sell shares while avoiding potential accusations of insider trading.
Stakeholder Impact
- Minimal impact on shareholders as the transaction was pre-planned and represents a small portion of the director's total holdings.
Next Steps
- No future actions or milestones mentioned.
Key Dates
| Date | Description |
|---|---|
| 09/12/2025 | Date the Rule 10b5-1 trading plan was adopted. |
| 06/15/2026 | Date of the option exercise and subsequent share sale. |
| 06/16/2026 | Date the Form 4 was filed with the SEC. |
Keywords
Ionis Pharmaceuticals, IONS, Insider Trading, Form 4, Stock Option Exercise, Biotech
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.